Skip to main content

Table 1 Baseline characteristics of haematology patients with acute respiratory failure

From: Validation of the Pneumocystis pneumonia score in haematology patients with acute respiratory failure

  PCP (n = 13) No-PCP (n = 128) P value
Age, year 54.0 (49.0–64.0) 59.0 (49.0–65.0) 0.585
Sex, male 12 (92.3) 78 (60.9) 0.052
Underlying disease
 Myeloid disease    0.896
 Acute/chronic myeloid leukaemia 4 (30.8) 40 (31.2)  
 Myelodysplastic syndrome 1 (7.7) 16 (12.5)  
 Other myeloid disease 1 (7.7) 6 (4.7)  
Lymphoproliferative disease
 Acute/ chronic lymphocytic leukaemia 2 (15.4) 21 (16.4)  
 Non-Hodgkin lymphoma 4 (30.8) 26 (20.3)  
 Myeloma 0 (0.0) 10 (7.8)  
 Hodgkin lymphoma 0 (0.0) 4 (3.1)  
 Others 1 (7.7) 5 (3.9)  
Stem cell transplantation    0.492
 Allogenic 2 (15.4) 40 (31.2)  
 Autologous 11 (7.7) 8 (6.2)  
Oncologic malignancy 2 (15.4) 4 (3.1) 0.172
Steroid user    0.740
 High-dose steroids 2 (15.4) 32 (25.0)  
 More than 3 months 2 (15.4) 11 (8.6)  
 Within 1 month 2 (15.4) 14 (10.9)  
 Dose of steroid over the duration, mg (prednisolone equivalent) 2155 (350–4000) 2750 (900–5303) 0.661
 Duration, days 48.0 (12.0–163.0) 62.0 (25.0–165.0) 0.566
Specific drugs    0.084
 T-cell immunosuppressors 1 (14.3) 32 (43.2)  
 Immune checkpoint inhibitor 2 (28.6) 4 (5.4)  
Bactrim prophylaxis* 0 (0.0) 30 (23.4) 0.107
  1. Values are given as median (interquartile range) or number (percentage)
  2. PCP Pneumocystis pneumonia
  3. *Defined as prescribed according to the patient (or relatives); adherence was not assessed